<![CDATA[Alligator Bioscienes - Halvårsrapport 2019]]>

<![CDATA[Alligator Bioscienes - Halvårsrapport 2019]]>Alligator Bioscience AB (publ) Interim report January-June 2019

"The results that Janssen presented at ASCO show that ADC-1013 can be administered in considerably higher doses than any of the other CD40 antibodies in clinical development. The study also shows early signs of clinical efficacy", CEO Per Norlén comments.

This link will take you to a page that’s not on LinkedIn

(lnkd.in)

https://lnkd.in/g-PW2df #immunooncology

]]>https://dev.proinvestor.com/forum/topic/440185/alligator-bioscienes-halvrsrapport-2019RSS for NodeWed, 15 Jul 2026 12:07:39 GMTThu, 11 Jul 2019 05:42:34 GMT60